New International Council on Biotechnology Associations advocates biotechnology growth.
The Biotechnology Industry Organization (BIO) is reporting that an international confederation of biotechnology trade associations has created the International Council on Biotechnology Associations (ICBA) to advocate for public policies that support worldwide biotechnology growth. BIO’s president and CEO, Jim Greenwood, has been elected to serve as ICBA Chairman, and Nathalie Moll, secretary general of EuropaBio, was elected Vice Chair.
“The increasingly global biotechnology industry provides breakthrough products and technologies that combat debilitating and rare diseases, reduce our environmental footprint, feed the hungry, use less and cleaner energy, and have safer, cleaner and more efficient industrial manufacturing processes,” said Greenwood in a press release. “However, the biotechnology sector faces both challenges and opportunities that cross borders. In forming the ICBA, our industry is taking an important step that allows us to better coordinate, organize and face these issues around the world together."
“Biotechnology is geared at enhancing our quality of life and responding to society’s grand challenges such as an ageing and ever increasing population, healthcare choice and affordability, resource efficiency, food security, climate change, energy shortages and economic growth,” said Moll in the press release. “The ICBA will advocate for more efficient and effective governance, science-based regulatory systems and the right framework conditions for competitiveness and innovation to ensure faster and more equitable access to biotech products and processes for patients, farmers and consumers around the world.”
Source:
BIO.org
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.